VEGFR3/Flt-4 Antibody (RM0003-5F63) [CoraFluor™ 1]

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

FLT4, a VEGF Receptor type protein kinase, is an endothelial cell-specific receptor. Binding of the extracellular domain of FLT4 to the vascular endothelial growth factor-related protein VEGF-C stimulates tyrosine phosphorylation and mitogenesis of endothelial cells. FLT4 (-/-) mice have been shown to have defective blood vessel development in early embryos and to experience cardiovascular failure at embryonic day 9.5. A mutation in the FLT4 gene has been implicated in human hereditary lymphedema type I. Similarly, a mutation in the conserved catalytic domain of FLT4, in close proximity to the FLT4 mutations in human primary lymphedema, has been linked to the Chy mouse mutant.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB110-61018CL1

• VEGFR3/Flt-4 Antibodies
• VEGFR3/Flt-4 Antibody Pair
• VEGFR3/Flt-4 ELISA Kits
• VEGFR3/Flt-4 Lysate
• VEGFR3/Flt-4 Proteins
• VEGFR3/Flt-4 ELISAs
• VEGFR3/Flt-4 Proteins and Enzymes